Concepedia

Thomas Kornecook

TK

12

Publications

421

Citations

12

H-Index

2009

Active since

Affiliations

Amgen (United States)(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Thomas Kornecook is an author at Amgen (United States) specializing in neuroscience, medicine, and pharmacology.

Top concepts

Publications per year

2009–2019

12

Publications

12

Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity

Russell F. Graceffa, Alessandro A. Boezio, Jessica Able et al. · Journal of Medicinal Chemistry · 2017 · 66 citations · Full text

Pharmacologic Characterization of AMG8379, a Potent and Selective Small Molecule Sulfonamide Antagonist of the Voltage-Gated Sodium Channel NaV1.7

Thomas Kornecook, Ruoyuan Yin, Stephen M. Altmann et al. · Journal of Pharmacology and Experimental Therapeutics · 2017 · 52 citations

Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities

Matthew M. Weiss, Thomas A. Dineen, Isaac E. Marx et al. · Journal of Medicinal Chemistry · 2017 · 49 citations · Full text

Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective Na<sub>V</sub>1.7 Inhibitors

Erin F. DiMauro, Stephen M. Altmann, Loren Berry et al. · Journal of Medicinal Chemistry · 2016 · 42 citations · Full text

, , +13

Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement

Isaac E. Marx, Thomas A. Dineen, Jessica Able et al. · ACS Medicinal Chemistry Letters · 2016 · 37 citations · Full text

Rows per page

1–5 of 12